Market Closed -
Nasdaq
16:00:00 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
3.18
USD
|
-3.20%
|
|
+4.95%
|
-5.92%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
444.8
|
121.3
|
119.5
|
-
|
-
|
Enterprise Value (EV)
1 |
258.2
|
3.326
|
71.75
|
-121.2
|
36.14
|
P/E ratio
|
-5.79
x
|
-1.59
x
|
-1.56
x
|
-1.61
x
|
-1.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
104
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-105
x
|
-
|
EV / EBITDA
|
-3.75
x
|
-0.04
x
|
-0.68
x
|
0.92
x
|
-0.23
x
|
EV / FCF
|
-3.91
x
|
-0.05
x
|
-0.79
x
|
1.2
x
|
-0.26
x
|
FCF Yield
|
-25.6%
|
-2,136%
|
-126%
|
83.2%
|
-386%
|
Price to Book
|
2.35
x
|
1.04
x
|
2.89
x
|
3.38
x
|
3.46
x
|
Nbr of stocks (in thousands)
|
35,581
|
35,877
|
37,584
|
-
|
-
|
Reference price
2 |
12.50
|
3.380
|
3.180
|
3.180
|
3.180
|
Announcement Date
|
23-03-21
|
24-03-26
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.15
|
-
|
EBITDA
1 |
-
|
-
|
-68.81
|
-88.47
|
-104.8
|
-131.5
|
-156.7
|
EBIT
1 |
-
|
-42.41
|
-68.88
|
-88.87
|
-95.83
|
-113.5
|
-145.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-9,867.42%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-43.28
|
-68.3
|
-82.64
|
-91.97
|
-115.2
|
-142.5
|
Net income
1 |
-28.55
|
-43.28
|
-68.3
|
-82.64
|
-89.54
|
-108.8
|
-142.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-9,464.07%
|
-
|
EPS
2 |
-21.16
|
-28.26
|
-2.160
|
-2.130
|
-2.039
|
-1.980
|
-1.958
|
Free Cash Flow
1 |
-
|
-39.22
|
-66.07
|
-71.04
|
-90.74
|
-100.9
|
-139.6
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-8,773.25%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-10-08
|
22-03-25
|
23-03-21
|
24-03-26
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.98
|
-15.33
|
-17.04
|
-17.64
|
-18.87
|
-20.78
|
-21.91
|
-22.32
|
-23.86
|
-21.42
|
-23.6
|
-23.78
|
-24.24
|
-23.9
|
-25.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.98
|
-15.33
|
-17.02
|
-17.5
|
-18.46
|
-19.8
|
-20.17
|
-20.5
|
-22.17
|
-19.94
|
-22.98
|
-23.69
|
-24.45
|
-23.6
|
-25.3
|
Net income
1 |
-12.98
|
-15.33
|
-17.02
|
-17.5
|
-18.46
|
-19.8
|
-20.17
|
-20.5
|
-22.17
|
-19.94
|
-23.07
|
-21.86
|
-22.47
|
-23.6
|
-25.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-8.280
|
-0.5800
|
-0.6000
|
-0.5300
|
-0.4800
|
-0.5100
|
-0.5200
|
-0.5300
|
-0.5700
|
-0.5000
|
-0.5538
|
-0.4538
|
-0.4675
|
-0.4700
|
-0.4650
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-25
|
22-05-12
|
22-08-08
|
22-11-10
|
23-03-21
|
23-05-10
|
23-08-08
|
23-11-07
|
24-03-26
|
24-05-07
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
91.4
|
187
|
118
|
47.8
|
241
|
83.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-39.2
|
-66.1
|
-71
|
-90.7
|
-101
|
-140
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-48.5%
|
-54.1%
|
-121%
|
-224%
|
-194%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
5.310
|
3.240
|
1.100
|
0.9400
|
0.9200
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.2
|
0.92
|
0.67
|
2.19
|
2.03
|
3.36
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
176.64%
|
-
|
Announcement Date
|
21-10-08
|
22-03-25
|
23-03-21
|
24-03-26
|
-
|
-
|
-
|
Last Close Price
3.18
USD Average target price
18.57
USD Spread / Average Target +484.01% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.92% | 120M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|